SCHEDULE 13D/A: Fortress Biotech Boosts Stake in Checkpoint Therapeutics to 13.5% Through Equity Grants, Solidifying Control

Fortress Biotech, Inc. has increased its beneficial ownership in Checkpoint Therapeutics, Inc. to 13.5% of outstanding common stock, primarily through recent equity grants, reinforcing its significant voting control.

Summary

• Fortress Biotech, Inc. (the "Reporting Person") has filed an Amendment No. 9 to its Schedule 13D, reporting an increase in its beneficial ownership of Checkpoint Therapeutics, Inc. (the "Issuer") common stock.
• As of December 31, 2024, Fortress Biotech beneficially owns 6,903,749 shares of the Issuer's common stock, representing 13.5% of the total outstanding shares.
• This increase in ownership is primarily due to the Issuer's issuance of 81,407 shares as an Offering Equity Grant and 2,386,808 shares as an Annual Equity Grant.
• These grants are made pursuant to an Amended and Restated Founders Agreement between Fortress Biotech and Checkpoint Therapeutics.
• Fortress Biotech holds 700,000 shares of the Issuer's Class A common stock, which grants it significant voting power (1.1 times the fraction of outstanding common stock to Class A common stock), enabling it to control or significantly influence all matters requiring stockholder approval, including director elections and mergers.
• The beneficial ownership also includes 100,000 shares of common stock underlying Warrants held by Fortress Biotech's Chairman, President, and CEO, Lindsay A. Rosenwald, M.D., and Executive Vice Chairman, Michael S. Weiss, exercisable at $1.29 per share until July 15, 2035.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive for Fortress Biotech due to increased control and ownership, but neutral to slightly negative for Checkpoint Therapeutics' minority shareholders due to potential dilution and concentrated control.

Positives

• Fortress Biotech has increased its beneficial ownership in Checkpoint Therapeutics, demonstrating continued commitment and investment in the Issuer.
• The acquisition of additional shares through equity grants strengthens Fortress Biotech's strategic influence and control over Checkpoint Therapeutics' corporate decisions, including board elections and potential mergers.
• The Founders Agreement provides a structured mechanism for Fortress Biotech to receive ongoing equity fees, aligning its long-term interests with Checkpoint Therapeutics' growth and financing activities.

Negatives

• The issuance of new shares as equity grants could lead to dilution for existing minority shareholders of Checkpoint Therapeutics.
• Fortress Biotech's significant voting control through its Class A common stock (1.1 times voting power) may limit the influence of other shareholders on corporate governance and strategic direction.

Risks

• **Corporate Control and Governance**: Fortress Biotech's ownership of Class A common stock grants it disproportionate voting power, allowing it to control or significantly influence all matters requiring stockholder approval, potentially at the expense of minority shareholder interests.
• **Share Dilution**: The ongoing issuance of common stock to Fortress Biotech as Offering Equity Grants (2.5% of gross equity/debt financing) and Annual Equity Grants (2.5% of fully-diluted outstanding equity) will lead to continued dilution for other shareholders.
• **Related Party Influence**: The significant roles of Fortress Biotech executives (Dr. Rosenwald and Mr. Weiss) on Checkpoint Therapeutics' Board of Directors, combined with Fortress Biotech's controlling stake, could raise concerns about potential conflicts of interest in decision-making.

Future Outlook

The document primarily details a change in beneficial ownership and does not provide explicit forward-looking statements or guidance regarding Checkpoint Therapeutics' future operations or financial performance. However, the continued equity grants to Fortress Biotech suggest an ongoing financial relationship and potential for future capital raises by Checkpoint Therapeutics.

Industry Context

This filing reflects a common dynamic in the biotechnology and pharmaceutical sectors where a founding or major investor maintains significant control and financial ties to a spin-off or portfolio company. Fortress Biotech's business model involves acquiring, developing, and commercializing novel products, often through subsidiary companies like Checkpoint Therapeutics. The continued equity grants underscore the financial and strategic interdependence between the parent and its portfolio company, which is a recognized model in venture-backed biotech development.

Corporate Governance

Related Party Transactions

• **Founders Agreement**: An Amended and Restated Founders Agreement between Fortress Biotech, Inc. and Checkpoint Therapeutics, Inc. dictates the issuance of equity fees (Offering Equity Grant) and annual equity grants (Annual Equity Grant) to Fortress Biotech.
• **Warrants**: Fortress Biotech issued Common Stock Warrants to its Chairman, President, and CEO, Lindsay A. Rosenwald, M.D., and Executive Vice Chairman, Michael S. Weiss, for 100,000 shares of Checkpoint Therapeutics common stock, exercisable until July 15, 2035, at $1.29 per share. Fortress Biotech must reserve shares from its holdings for these warrants.

Stakeholder Impact

• **Shareholders**: Existing minority shareholders may experience dilution due to the issuance of new shares to Fortress Biotech. The concentrated voting power of Fortress Biotech could also reduce the influence of other shareholders on corporate decisions.
• **Management/Employees**: The continued strategic relationship with Fortress Biotech, including the presence of its executives on the board, provides stability and strategic direction for Checkpoint Therapeutics' management and employees.
• **Creditors/Investors**: The ongoing equity grants tied to financing activities suggest a continued need for capital by Checkpoint Therapeutics, which could be a factor for potential creditors or investors assessing the company's financial health and funding strategy.

Next Steps

• Checkpoint Therapeutics is expected to continue issuing annual equity grants to Fortress Biotech as per the Founders Agreement.
• Fortress Biotech may continue to exercise its significant voting influence on Checkpoint Therapeutics' corporate matters, including future director elections and strategic transactions.

Key Dates

Keywords

Fortress Biotech, Checkpoint Therapeutics, SEC filing, Schedule 13D, beneficial ownership, equity grants, Class A common stock, voting control, corporate governance, share dilution, related party transactions, biotechnology, pharmaceuticals